SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-032779
Filing Date
2023-09-21
Accepted
2023-09-21 16:15:45
Documents
12
Period of Report
2023-09-19
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K gthx-20230919.htm   iXBRL 8-K 26536
  Complete submission text file 0001628280-23-032779.txt   155471

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20230919.xsd EX-101.SCH 1922
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20230919_lab.xml EX-101.LAB 24851
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20230919_pre.xml EX-101.PRE 13060
6 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20230919_htm.xml XML 2833
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 231269278
SIC: 2834 Pharmaceutical Preparations